Classement en actions
#34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Prix de l'action
$0.6379482
Dernière synchronisation: 2023-05-22
Capitalisation boursière
$5.98M
Changement (1 jour)
-0.44%
Le prix COX avec la capitalisation boursière de B
Capitalisation boursière de Nicox S.A.(COX)
Capitalisation boursière: $5.98M
En August 2026, Nicox S.A. a une capitalisation boursière de $5.98M. Cela fait de Nicox S.A. la 34243rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Nicox S.A. du 2000 au 2026
COX par rapport au top 5 des plus populaires stocks
| Prix pour COX |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+91,209,925.47%
|
|
|
|
|
$4.490T
|
+75,118,166.62%
|
|
|
|
|
$4.162T
|
+69,637,181.89%
|
|
|
|
|
$3.676T
|
+61,505,296.67%
|
|
|
|
|
$2.833T
|
+47,396,847.74%
|
